Olaptesed pegol

Drug Profile

Olaptesed pegol

Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NOXXON Pharma AG
  • Class Antineoplastics; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Chemokine CXCL12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma
  • Phase I/II Colorectal cancer; Pancreatic cancer
  • No development reported Glioblastoma
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glioblastoma in Germany (SC)
  • 01 Apr 2017 NOXXON completes a phase IIa trial in Chronic lymphocytic leukaemia (Combination therapy, Recurrent, Treatment experienced) (IV) in Austria, France, Belgium and Italy (NCT01486797)
  • 09 Mar 2017 Phase-I/II clinical trials in Colorectal cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV) (EudraCT2016-003657-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top